This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Oct 2010

Galapagos and NCI sign US$5m deal

The South San Francisco-based Compound Focus subsidiary of Galapagos’ BioFocus service division will provide compound management services to the US National Cancer Institute (NCI) in a three-year deal worth up to US$5m.

The South San Francisco-based Compound Focus subsidiary of Galapagos’ BioFocus service division will provide compound management services to the US National Cancer Institute (NCI) in a three-year deal worth up to US$5m, with two, one-year extension options.

Under the agreement, Compound Focus will establish a Small Molecule Repository for the NCI Chemical Biology Consortium (CBC). This will form part of the CBC''s drug discovery and development platform for new oncology therapeutics being researched by a consortium of academic institutions.

‘Compound Focus has done very well to expand its long-standing relationship with the NIH into this new project with the NCI,’ said Onno van de Stolpe, ceo of Galapagos.

‘Our compound management facility has met or exceeded its revenue objectives since we acquired it in 2006, making it a solid contributor to our service division's revenue stream.’

Related News